UK markets close in 3 hours 12 minutes

NVO May 2024 155.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
30.550.00 (0.00%)
As of 03:31PM EDT. Market open.
Full screen
Previous close30.55
Open30.55
Bid21.20
Ask23.95
Strike155.00
Expiry date2024-05-17
Day's range30.55 - 30.55
Contract rangeN/A
Volume3
Open interestN/A
  • Reuters

    Eli Lilly's diabetes drug tirzepatide gets approval in China

    SHANGHAI (Reuters) -Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market. Novo Nordisk's popular diabetes drug Ozempic won approval from China in 2021 and the company saw sales of the weekly injection in the greater China region that includes Hong Kong and Taiwan double to 4.8 billion Danish Krone ($698 million) last year. Eli Lilly did not say when sales would begin in China or how many doses would be supplied.

  • Barrons.com

    Hims & Hers Stock Spikes. It’s Taking on Big Pharma With Cheap Obesity Shots.

    A relatively small telehealth company that recently went public wants to take a slice of the big pharmaceuticals companies’ hottest market. Hims & Hers Health said on Monday that it is offering weight-loss injections for as low as $199 a month, a move that capitalizes on the growing demand for such treatments. The telehealth platform started offering oral medication kits for weight loss late last year and is now expanding its roster of products as it seeks to compete with companies like Eli Lilly and Novo Nordisk.

  • Benzinga

    Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals

    Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond strongly to Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy (semaglutide). The study, presented at the Digestive Disease Week meeting in Washington, found a 95% likelihood that patients with this genetic profile would be strong responders to the treatment. Related: Changing Frugal Eating Habits-How Novo Nordisk/Eli Lilly’s Weight Loss Drugs Reshaping Food Spending. Th